Company Overview of Ontario Institute For Cancer Research
101 College St Suite 800
Toronto, ON M5g 1l7
Founded in 2001
Key Executives for Ontario Institute For Cancer Research
President and Scientific Director
Deputy Director and Chief Scientific Officer
Compensation as of Fiscal Year 2015.
Ontario Institute For Cancer Research Key Developments
The Ontario Institute for Cancer Research and Novera Therapeutics Collaborate with Janssen Biotech
Oct 16 15
The Ontario Institute for Cancer Research and Novera Therapeutics have collaborated with Johnson & Johnson's Janssen Biotech. The collaboration is aimed at accelerating the development of small molecule drugs for haematological cancers. By collaborating with University Health Network, Novera intends to discover and develop novel therapeutic compounds identified through Ontario Institute for Cancer Research's drug discovery programme. The firm will coordinate the partnership with Janssen under a license option and exclusive license agreement. The contract will see Novera receive an upfront payment and make it eligible to receive various pre-clinical, clinical, regulatory and commercialisation payments up to a total of around CAD 450 million. Janssen Biotech has been granted an exclusive option to license candidate drugs that have been identified through the collaboration, for all human uses globally. The firm will also manage responsibility for subsequent pre-clinical, clinical and commercial development upon exercising of its option. Under the collaboration, The Ontario Institute for Cancer Research will identify, fund and support oncology innovations in a bid to improve clinical practice.
Ontario Institute for Cancer Research Extends Collaboration with Janssen Inc. to Develop Clinical Trials for Prostate Cancer
Feb 25 15
The Ontario Institute for Cancer Research (OICR) is extending its collaborative research partnership with Janssen Inc. to develop more multi-centre clinical trials and other translational research projects that address important clinical questions in prostate cancer. The new funds will be made available to qualifying researchers at cancer centres across Canada who are addressing important clinical questions in prostate cancer. The funding will be dispersed to researchers through the Canadian Cancer Clinical Trials Network, which is based at OICR, through an open application process.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries